Tin tức & Cập nhật
Lọc theo Chuyên ngành:
![Gene mutations may provide clues for liver cancer survival](https://sitmspst.blob.core.windows.net/images/articles/molecules-689577b6-c2b6-48d0-8b95-db10b2bb226b-square.jpg)
Gene mutations may provide clues for liver cancer survival
Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.
Gene mutations may provide clues for liver cancer survival
13 Oct 2021![Mediterranean diet may brighten outlook in polyvascular atherosclerotic disease](https://sitmspst.blob.core.windows.net/images/articles/olive-oil-supplemented-mediterranean-diet-may-delay-glucose-lowering-medication-initiation-f0cb9537-7c15-4c8d-85c5-c308fc490284-square.jpg)
Mediterranean diet may brighten outlook in polyvascular atherosclerotic disease
Adherence to a Mediterranean dietary pattern among polyvascular atherosclerotic disease (PAD) patients leads to improvements in inflammatory and metabolic status, which may potentially translate into better long-term cardiovascular outcomes, according to a study.
Mediterranean diet may brighten outlook in polyvascular atherosclerotic disease
13 Oct 2021![Older age, CRP portend deaths in COVID-19 patients with diabetes](https://sitmspst.blob.core.windows.net/images/articles/c-react-4357adf9-946a-41f8-82f3-a11c6729d678-square.jpg)
Older age, CRP portend deaths in COVID-19 patients with diabetes
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.
Older age, CRP portend deaths in COVID-19 patients with diabetes
13 Oct 2021![Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies](https://sitmspst.blob.core.windows.net/images/articles/cancercell-4315869d-e51a-4f60-90f4-85b44ec5d366-square.jpg)
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
While patients with haematological malignancies (HM) are able to mount a persistent antibody response against the spike (S) protein of the SARS-CoV-2 virus, early treatment with rituximab completely abolishes such response, a recent study has found. These findings could help inform coronavirus disease 2019 (COVID-19) vaccination policies for patients with HMs.
Rituximab suppresses anti-S COVID-19 antibodies in patients with haematological malignancies
12 Oct 2021![Ticagrelor after abbreviated DAPT minimizes bleeding while preserving efficacy in ACS](https://sitmspst.blob.core.windows.net/images/articles/cardiovascular-magnetic-resonance-coronary-heart-disease-ct-scan-feadea7d-a96e-42de-8a50-9c63eee5111f-square.jpg)
Ticagrelor after abbreviated DAPT minimizes bleeding while preserving efficacy in ACS
Monotherapy with ticagrelor after a month-long course of dual antiplatelet (DAPT) with ticagrelor plus aspirin works to reduce the risk of bleeding without compromising ischaemic outcomes among patients with acute coronary syndrome (ACS) as compared with guideline-recommended treatment with 12-month DAPT followed by aspirin monotherapy, according to data from the GLOBAL LEADERS trial.
Ticagrelor after abbreviated DAPT minimizes bleeding while preserving efficacy in ACS
12 Oct 2021![Sustained caloric restriction reduces more fat than muscle, organ tissue](https://sitmspst.blob.core.windows.net/images/articles/mdccnadit2dmweightloss-2c5c9d3e-54ec-444c-ba4f-5d78b1f72372-square.jpg)
Sustained caloric restriction reduces more fat than muscle, organ tissue
Calorie restriction (CR) for 2 years in young individuals without obesity significantly impacts body composition, including a preferential loss of adipose tissue, such as visceral fat, over muscle and organ tissue, a recent study has shown.
Sustained caloric restriction reduces more fat than muscle, organ tissue
12 Oct 2021![Linaclotide reduces abdominal symptoms in IBS-C](https://sitmspst.blob.core.windows.net/images/articles/fotolia107671251-f19d014e-89d6-44da-82ee-ef8e1dd863bf-square.jpg)
Linaclotide reduces abdominal symptoms in IBS-C
Use of linaclotide results in a significant reduction in several abdominal symptoms, such as bloating, discomfort, and pain, among patients with constipation-predominant irritable bowel syndrome (IBS-C) as compared with placebo, according to a study. In addition, reported adverse events (AEs) are in line with the established safety profile.